AlbertsenP.C.AaronsonN.K.MullerM.J.KellerS.D.WareJE.Health-related quality of life among patients with metastatic prostate cancer.Urology 1997;49: 207–217.
2.
ArmitageJ.O.PotterJF.Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age.J Am Geriatr Soc 1984;32: 269.
BeggC.B.CarbonePP.Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group.Cancer 1983;52: 1986–1992.
5.
BennettL.M.MussH.B.DoroshowJ.H.A randomized multicenter trial comparing mitoxantrone, cyclophosphamide and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil in the therapy of metastatic breast carcinoma.J Clin Oncol 1988;6: 1611–1620.
6.
CapriG.GianniL.Terapia antiblastica e sue problematiche. In: La patologia mammaria in età senile, GalanteE.L. (Ed.), II Pensiero Scientifico Editore Roma, 1998, pp 195–196.
7.
ChristmanK.MussH.B.CaseL.D.Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience.JAMA 1992;268: 57–62.
8.
DenMeadeS.R.IsaacsJT.Prostate cancer: where are we and where are we going?Br J Urol 1997;79(Suppl 1): 2–7.
9.
DixonD.O.NeilanB.JonesS.E.Effect of age in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience.J Clin Oncol 1986;4: 295–305.
10.
Early Breast Cancer Trialists’ Collaborative Group.Tamoxifen for early breast cancer: an overview of the randomised trials.Lancet 1998;351: 1451–67.
11.
EisenbergerMA.Chemotherapy of advanced prostate cancer. In: The Medical Management of Prostate Cancer II, DenisL (Ed.), Springer VerlagBerlin, 1991, pp. 74–88.
12.
EsteveJ.KickerA.FerlayJ.ParkinDM (Eds): Facts, and figures of cancer in the European Community.IARC Scientific Pubblications, Lyon49, 1993.
13.
GerhartzH.H.EngelhardM.MeusersP.Randomized, double-blind, placebo controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin lymphomas.Blood1993; 82: 2329.
14.
GlickJ.H.GelberR.D.GoldhirschA.SennHJ.Meeting Highlights: adjuvant therapy for primary breast cancer.J Natl Cancer Inst 1995;87: 1479–1485.
HormJ.W.SondikEJ.Person-years of life due to cancer in the United States, 1970 and 1984.Am J Public Health1989; 79: 1490–1493.
17.
MettlinÇ.Changes in patterns of prostate cancer care in the USA: Results of American College of Surgeons Commission on Cancer Studies.The Prostate 1997;32: 221–226.
18.
MussHB.Breast cancer in older women.Seminars Oncol 1996;23(Suppl 2): 82–88.
19.
NewlingDWW.The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials.Br J Urol 1997;79(suppl 1): 72–81.
20.
RepettoL.SimoniC.VenturinoA.Mitoxantrone in elderly women with advanced breast cancer: a phase II study.Anticancer Research 1995;15: 2297–2300.
21.
PettengelR.GurneyH.RadfordJ.A.Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.Blood 1992;80: 1430.
22.
ShippM.A.HarringtonD.P.AndersonJ.R.A predictive model for aggressive NHL.The International non-Hodgkin lymphoma prognosic factor project. N Engl J Med 1993;29: 987–994.
23.
Stuart-HarrisR.C.BozekT.PavlidisN.A.Mitoxantrone: an active new agent in the treatment of advanced breast cancer.Cancer Chemother Pharmacol 1984;12: 1–4.
24.
TannockI.F.OsobaD.StockierM.R.ErnstS.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.J Clin Oncol 1996;14: 1756–1764.
25.
ZinzaniP.L.BendandiM.GherlinzoniF.VNCOP-B regimen in the treatment of high-grade non-Hodgkin lymphoma in the elderly.Haematologica 1993;78: 378–382.
26.
ZinzaniP.L.PavoneE.StortiE.Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.Blood 1997;89: 3974–3979.
